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Abstract
Background The World Health Organization estimates that over 50% medicines are prescribed inappropriately and the main 
driver of antimicrobial resistance globally. There have only been a limited number of studies evaluating prescribing patterns 
against national standard treatment guidelines (STGs) in sub-Saharan African countries including Namibia. This is important 
given the high prevalence of both infectious and non-infectious diseases in sub-Saharan Africa alongside limited resources. 
Objective Our aim was to assess prescribing practices and drivers of compliance to National guidelines among public health 
care facilities in Namibia to provide future guidance. Setting Three levels of public healthcare in Namibia. Method A mixed 
method approach including patient exit and prescriber interviews at three levels of health care in Namibia, i.e. hospital, health 
centre and clinic. Main outcome measures Medicine prescribing indicators, compliance to and attitudes towards National 
guidelines. Results Of the 1243 prescriptions analysed, 73% complied with the STGs and 69% had an antibiotic. Of the 
3759 medicines (i.e. mean of 3.0 ± 1.1) prescribed, 64% were prescribed generically. The vast majority of prescribers were 
aware of, and had access to, the Namibian STGs (94.6%), with the majority reporting that the guidelines are easy to use 
and they regularly refer to them. The main drivers of compliance to guidelines were programmatic, that is access to up-to 
date objective guidelines, support systems for continued education on their use, and ease of referencing. Lack of systems to 
regulate noncompliance impacted on their use. Conclusion Whilst the findings were encouraging, ongoing concerns included 
limited prescribing of generic medicines and high use of antibiotics. A prescribing performance management system should 
be introduced to improve and monitor compliance to prescribing guidelines in public healthcare.
Keywords Compliance · Namibia · Prescribing indicators · Prescribing patterns · Qualitative research · Standard treatment 
guidelines
Impact on practice
• There have only been a limited number of studies in sub-
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• This study shows that despite good access to standard 
treatment guidelines (STGs) by prescribers in Namibia, 
compliance to these guidelines is sub-optimal with high 
rates of antibiotic and brand name prescribing.
• Public healthcare systems in sub-Saharan Africa need to 
address programmatic barriers to enhance compliance to 
national guidelines
• Barriers to address to enhance the use of STGs include 
their design, the quality of evidence in the guidelines, 
the need for continued up-date guidance and education 
regarding their use, as well as systems to regularly audit 
prescribing practices.
• Pharmacists can play a key role in the development and 
dissemination of STGs including educating physicians 
on appropriate medicine use.
Introduction
The appropriate use of medicines is critical especially in 
lower- and middle-income countries (LMICs) where the 
cost of medicines account for up to 70% of total health-
care expenditure, with potentially catastrophic implications 
for the family if a member becomes ill [1, 2]. The World 
Health Organization (WHO) estimates that over half of all 
medicines are inappropriately prescribed, dispensed or sold 
worldwide, and a similar percentage of patients fail to take 
their medicine properly [2].
In Namibia, several medicine use surveys have suggested 
the inappropriate use of medicines across all levels of health 
care [3, 4]. This is a concern as currently in Namibia over 
45% of the adult population have hypertension [5], with car-
diovascular diseases now a leading cause of death (21%) [5, 
6]. There is also a high burden of infectious disease such 
as HIV/AIDS, tuberculosis, malaria and acute respiratory 
infections in Namibia [7–9]. In order to promote rational use 
of medicines (RUM), the Ministry of Health and Social Ser-
vices (MoHSS) adopted the Essential Medicine concept with 
the first National Medicine Policy launched in 1998, and the 
first standard treatment guidelines (NSTGs) was launched 
in 1994, with a comprehensive update in 2012 [9]. STGs 
are seen as important interventions to improve medicine use 
in countries including Namibia [9–11]. However, compli-
ance to the guidelines in 2014 was between 26.2 and 44.6% 
nationally [12], below the target of ≥ 90% with a rate of 80% 
considered acceptable [9].
Aim of the study
The objective is to investigate current trends in prescribing 
practices and compliance with NSTGs among different level 
health care facilities in Namibia. In addition, qualitatively 
identify key factors that may influence prescribing practices 
and NSTG compliance.
Ethics approval
Permission to conduct the research was granted by the Uni-
versity of Namibia (UNAM) and the Ministry of Health and 
Social Services (MoHSS, REF 17/3/3). Specific patient and 
prescriber identifiers and patient identifiers were not col-
lected but rather codes were assigned to each study partici-
pant for identification.
Methodology
Study design and setting
A cross-sectional descriptive survey applying mixed meth-
ods was conducted to assess medicine prescribing patterns 
and drivers of compliance to NSTGs at three levels of health 
care in Namibia. These were the Intermediate Hospital 
Katutura (IHK), Katutura Health Centre (KHC) and Khom-
asdal Clinic (KMDC) in the Khomas Region. The Khomas 
region was chosen as it has a diverse cosmopolitan patient 
and prescriber population, a high population versus other 
regions in Namibia and concerns with adherence to STGs 
[12]. The Khomasdal clinic was purposely selected among 
the ten clinics in the region based on its proximity and simi-
larity of demographics and services to IHK and KHC.
Quantitative methods were used to assess prescribing 
indicators based on those recommended by the WHO [9, 
13]. Qualitative methods were applied to evaluate thematic 
drivers of compliance to NSTGs.
Study population and sample
The target populations included outpatient prescriptions and 
prescribers at the three public health facilities. Prescriptions 
obtained from health passports during patient exit interviews 
were analysed for prescribing patterns. In Namibia, outpa-
tient prescriptions are compiled in a medical booklet, the 
health passport. These detail consultation records including 
diagnoses, medical and medication history. This study only 
included prescribing data on recent prescriptions at the three 
facilities. Consequently, a sample of 584 patient prescrip-
tions was determined using Kish and Leslie [14] method 
for a single sample estimation of proportion [9, 14]. How-
ever, since the study was conducted at two different levels of 
health care, we estimated the total sample at 2 * 584 = 1168. 
We included an additional 6.5% to account for prescriptions 
that may have missing data. As a result, a maximum number 
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of prescription records to be collected at patient exit inter-
views was 1243. These prescriptions were collected from 
1243 patients who were sampled from daily outpatient reg-
isters at the respective outpatient pharmacies at the three 
health facilities. A systematic sampling method, i.e. every 
third patient, was used to consecutively recruit patients. Of 
the 7 (0.56%) prescriptions with presenting complaints but 
no diagnosis indicated, 5 were rectified after consultation 
with the respective prescribers and the two were replaced 
through the process of systematic sampling matched with 
the age and sex of the patients.
Each prescription included information on patient demo-
graphics, diagnosis, medication and prescriber. Prescribers 
(both nurses or doctors) are required by law to indicate the 
diagnosis on the prescriptions as classified in the NSTGs. 
For prescriptions without a clear diagnosis, a team consist-
ing of a pharmacist, doctor and nurse reviewed the prescrip-
tions to link the diagnosis with the disease categories in the 
NSTG.
Secondly, prescribers who were on duty during the 
6 months study period, 1st February to 31 July 2015, were 
interviewed for drivers for compliance to NSTGs. The sam-
ple of prescribers was determined purposively. A total of 74 
prescribers working at the three public health facilities at 
the time of data collection were included. Of these, 44 were 
employed at IHK, 21 at KHC and 9 at KMDC. At any given 
time, 12 prescribers worked at OPD in IHK, 8 at KHC and 
5 at KMDC.
We used the duty rosters to identify prescribers work-
ing at out-patient departments in the selected three sites to 
include them in the sample. Using the roster, 40 prescribers 
were expected to work in three sites at OPD during the data 
collection period. All 40 prescribers were selected for pre-
scriber interviews. We did not include any prescribers in the 
inpatient department of IHK or any working in specialised 
clinics. Responses were broken down by prescriber type for 
further analysis.
Data collection procedure
Data were collected in two phases; patient exit interviews 
on medicine prescribing patterns and prescriber interviews 
using a structured questionnaire for drivers of compliance 
to NSTGs.
Patient exit‑interviews
Patients were recruited into the study using a systematic 
sampling technique, i.e. every third patient registered at the 
outpatient’s pharmacy.
Only patients that gave written informed consent were 
subsequently interviewed and prescriptions analysed. The 
1243 patients/patients were stratified by health facility, 
with the allocation calculated on the basis of patient turno-
ver resulting in KMDC (10%), KHC (35%) and IHK (55%). 
Only prescriptions from the general outpatient depart-
ment were selected. Prescribing data were abstracted from 
patients’ prescription booklets (i.e. health passports) by the 
researchers (QN and DK) and a team of three experienced 
data collectors using the WHO recommended tool for med-
icine use evaluation [13]. We also excluded prescriptions 
with incomplete information such as missing diagnosis or 
missing details of the patient. Two patients’ prescriptions 
had missing data on diagnosis. Data were quantitatively ana-
lysed to determine the prescribing indicators [9].
Survey of prescribers
A questionnaire (Annex 1) was administered to prescribers 
at the selected health facilities to assess for drivers of com-
pliance to NSTGs. The tool was piloted with the help of two 
intern doctors at IHK and standardized before being rolled 
out. Prescribers’ details were also collected.
Data to determine the level of compliance and the use of 
NSTGs in the prescribing of medicines was collected using 
a self-administered questionnaire. Only prescribers whose 
names appeared on the prescriptions evaluated in the first 
phase of the study were assessed. During the collection of 
the questionnaire, a structured interview was conducted 
with the prescribers to assess the availability and access to 
NSTGs as well as gain further insight on key factors that 
might impact on their prescribing practices and compliance 
to NSTGs. The interviews were structured in such a way that 
the answers could be thematically analysed and/or quantified 
for ease of analysis. All interviewees gave their informed 
consent before being interviewed.
Data analysis
The main outcome measures were medicine prescribing 
practices and qualitative determinants of compliance to 
NSTGs among public health care facilities in Namibia. 
Quantitative data from the patient exit and prescriber inter-
views were entered into Epidata 3.1 for management and 
exported to SPSS v24 for descriptive analysis of the indica-
tors and compliance to NSTGs.
Prescribing practices were analysed using descriptive sta-
tistics as per the WHO/INRUD indicators [9, 13]. The five 
indicators and the MoHSS targets include:
• Average number of medicines per out-patient prescrip-
tion
• The percentage of medicines prescribed by generic name
• Percentage of prescriptions with an antibiotic
• Percentage of prescriptions with an injection
• The level of compliance to STGs
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Quantitative and qualitative methods were applied to 
identify the drivers of compliance of NSTGs. Descrip-
tive statistical analysis was used to determine the level 
of awareness, availability, access, use, and training on 
NSTGs. The drivers of compliance to STGs were also 
quantitatively determined using the χ2 test with the level 
of significance (α) set at p = 0.05 and a 95% confidence 
interval, with qualitative data analysis conducted using 
thematic content analysis to identify the themes and 
subthemes of drivers of compliance to the NSTGs. The-
matic content analysis was performed manually from data 
obtained from the interviews. The content or responses 
to the question items were colour coded and organized 
into sub-themes. The significant drivers of compliance to 
NSTGs were subsequently converged during the analysis 
to support the themes.
Results
Demographics
A total of 37 prescribers were interviewed giving a 
response rate of 92.5% (37/40). Table 1 shows that the 
majority of the prescribers interviewed were from the hos-
pital and were medical officers.
Medicine prescribing practices
Compliance with NSTGs
The average number of medicines per prescription, the per-
centage prescribed by their generic/INN (International non-
proprietary) name and the percentage including an antibiotic 
are contained in Table 2. Table 2 also contains government 
targets. There was no statistical difference between the vari-
ous healthcare levels. Injections were prescribed in 10.8% of 
prescriptions, highest in hospital outpatients [9].
Out of the 1243 prescriptions, the majority complied with 
NSTG recommendations (Table 2), with compliance signifi-
cantly higher among PHC facilities [76.1% (n = 416/547)] 
than the hospital [70.5% (n = 491/696, p = 0.03)].
Awareness and utility of NSTGs
The majority of the prescribers (94.6%) were aware and 
had access to the NSTGs for reference purposes (Table 3), 
with 82% reporting that it is easy to use the NSTGs. 32.4% 
reported that they refer to NSTGs on a daily basis with 
Table 1  Distribution of 
prescribers by professional 
cadre and health facility
*(p < 0.05)-statistically significant—Pearson χ2 test
Demographic Prescriber cadre Total χ2 P value Cramer V
Medical Nursing
Facility level
Hospital 23 2 25 14.15 0.000* 0.681
PHC 4 8 12
Health facility
IHK 23 2 25 19.56 0.000* 0.727
KHC 2 8 10
KMDC 2 – 2
Cadre
Enrolled nurse – 4 4 37 0.000* 1
Medical intern 3 – 3
Medical officer 20 – 20
Registered nurse – 8 8
Student nurse – 2 2
Sources of information
Algorithm charts 0 2 2 17.7 0.013* 0.692
Ward protocols 1 – 1
Formularies 6 – 6
Leaflets – 1 1
Online resources 3 – 3
Medical textbooks 2 1 3
Treatment guidelines 4 5 9
No response 11 1 12
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18.9% once a week (Fig. 1). However, only 18.9% of pre-
scribers had received at least one training session on the use 
of the STGs (Table 3). 
Sources of information
Prescribers used a wide variety of references sources when 
prescribing medicines, ranging from patient leaflets to local 
and international STGs and/or treatment protocols.
48% used printed guidelines in the form of STGs, for-
mularies and algorithm charts when seeking sources of 
Table 2  Compliance with WHO 
INRUD Criteria including 
Namibian standard treatment 
guidelines. Adapted from [9, 
15]
WHO/INRUD indicator WHO targets Namibia ministry of 
health targets
Indicator measures
Target Acceptable
Average number of medicines per prescription < 2 < 2 2.5 3.0 ± 1.1
% of prescriptions with an antibiotic < 30% < 25% 35% 69%
% of prescriptions with an injection < 20% < 10% 15% 10.8%
% of medicines with generic name 100% 100% 80% 64%
Compliance to NSTG > 80% > 80% 73%
Table 3  Distribution of 
awareness and use of STGs by 
prescribers’ cadre
*(p < 0.05)-Statistically significant—Pearson χ2 test
Demographic Prescriber cadre Total χ2 P value Cramer V
Medical Nursing
Awareness of STG
Yes 25 10 35 0.783 0.376 0.145
No 2 – 2
Access to STG copy
Yes 26 9 35 0.566 0.452 0.124
No 1 1 2
Training on STG use
Yes 5 2 7 0.01 0.919 0.017
No 22 8 30
Frequency of STG use
Daily 7 5 12 3.905 0.563 0.325
Never 3 – 3
Once a month 8 3 11
Once a week 5 2 7
Once a year 1 – 1
Once in 6 months 3 – 3
Ease of STG use
Difficult 4 2 6 1.266 0.531 0.185
Easy 20 8 28
Advantages of STG use
Comprehensive 5 – 5 3.963 0.139 0.327
Easy indexing 10 7 17
No response 12 3 15
2.7%
8.1%
8.1%
18.9%
29.7%
32.4%
Once a year
Never
Once in 6 months
Once a week
Once a month
Daily
Fig. 1  Frequency of use of the STGs (n = 37)
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prescribing information (Fig. 2). The most used printed 
treatment guidelines were the NSTG; disease specific guide-
lines for HIV/AIDS, antiretroviral therapy, tuberculosis, 
malaria, and sexual transmitted infections; the South Afri-
can guidelines; the PHC manual; as well as flow charts and 
treatment protocols. Online sources of information included 
Medscape and Wikipedia. 
Main thematic drivers for compliance to NSTGs
The majority of the prescribers reported the simple indexing 
layout of the NSTGs, their access and tailored information, 
as the main factors driving their use (Table 4).
The principal factors included:
(a) Comprehensiveness of the STG: 5 responses sup-
ported the statement that the STGs cover the treatment 
and pathogenesis of common disease conditions at all 
levels of health care in Namibia. Some of the responses 
included; “Common diseases are found here, the treat-
ment and pathologic conditions are clear” and “Practi-
cal, straightforward and inclusion of most conditions”.
(b) Simple indexing system and easy to understand: 
17 responses confirmed the NSTGs are well laid out 
to facilitate quick identification of disease conditions 
and medicines. Two responses though were against 
the layout of the NSTG due to lack of time to make 
quick references (Table 3). Such responses included: 
“lack of time to page through the STG with high work-
loads” and “It is a bit difficult because you have to have 
enough time to sit and page back in the book and pre-
scribe from it”. Against this, 83% of responders agreed 
the NSTGs are simple, clear and easy to understand, 
have a good lay out and good use of a colour coding 
system. Some of the responses included: “Clear and 
easy to understand”, “each condition in STGs is clearly 
set out”, “They are easy to use because the index is 
clearly stating according to the alphabetical order plus 
the medicine index on conditions are separate which 
makes it even easier to use.” “Pages are coloured coded 
and the STG is easy to carry”. “Treatment is clearly 
laid out step by step; well compiled”.
(c) Access/availability of STGs by health workers: All 
three responses on this theme reported a lack of access 
and availability of NSTG copies: “We have to share 
the book so sometimes you have to wait for it if your 
colleagues are busy with it”. “They are not easily avail-
able”.
(d) Availability of recommended STG medicines at 
the facility: One response indicated the lack of cer-
tain medicines recommended by the STG demotivated 
them from using the STG: “Some medications are not 
in stock that is supposed to be used according to the 
1 0 0
3 2
6
4
11
0 1 2
0 1
0 5
1
Medical Nurse
2= 17.7;  
p = 0.013
Fig. 2  Sources of information used when prescribing medicines 
(n = 37)
Table 4  Factors promoting the 
use of STGs
*(p < 0.05)-Statistically significant—Pearson χ2 test
Demographic Prescriber cadre Total χ2 P value Cramer V
Medical Nursing
Pros for STG use
Comprehensive 5 – 5 3.963 0.139 0.327
Easy indexing 10 7 17
No response 12 3 15
Cons for STG use
Access to STGs 2 4 6 11.346 0.078 0.554
Access to medicines 2 – 2
Information overload 2 3 5
Out-dated; needs review 3 – 3
Does not fit in pocket 2 – 2
No response 16 3 19
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STG”. However, two responses reported that the medi-
cines found in the STGs are available.
(e) Relevance of information to health care cadre or 
health facility level: Two prescribers indicated that the 
information in the STG is not structured for application 
by different prescribers - certain aspects are irrelevant 
or challenging to understand. Responses included: 
“Information is not clear on how to give the treatment 
and there are no second choices in case if the medicines 
are not available”.
(f) Portability of the STG: Concerns (2 responses) 
included; “Not pocket fit. It is too thick, difficult to 
carry around”
(g) Updated or objective information: There was one 
response that the information in the STG is not up-to-
date as well as trusting the evidence in the STGs: “Not 
evidenced based”
Remedial strategies for effective use of NSTGs 
in prescribing of medicines
The prescribers suggested a number of interventions to 
improve compliance which are contained in Table 5.
Discussion
We believe this is the first study to qualitatively identify key 
factors influencing prescribing practices and NSTG compli-
ance across disease areas building on assessments of guide-
line adherence in specific treatment and disease areas as well 
as ways to improve the content and pragmatism of national 
STGs among sub-Saharan African countries [10, 16–18]. 
This is a concern given the high prevalence of both infec-
tious and non-infectious diseases in sub-Saharan Africa and 
their impact on morbidity, mortality and costs [5, 19–27].
The prescribing indicators were typically sub-optimal 
compared with the Namibia and WHO/INRUD standards, 
similar to other African countries [9, 15]. However, 73% of 
prescriptions were compliant to NSTG recommendations, an 
improvement on previous studies in Namibia [12], compar-
ing favourably with recent studies among PHCs in Botswana 
and other LMICs [28–31]. However, lower than the compli-
ance level set at 85% for Namibia [9], with ongoing concerns 
that antibiotic prescribing remains suboptimal [9].
Encouragingly, there was a high level of awareness 
and availability (94.6%) of the NSTGs among prescribers 
(Table 2), similar to the previous study by Akpabio et al. in 
Namibia and Matsitse et al. in South Africa [12, 31]. This 
compares with variable availability of STGs among PHCs 
in Botswana [32]. However, 8.1% of prescribers in Namibia 
had never seen a copy of the NSTG (Fig. 1) and never made 
reference to the NSTG in their prescribing. Encouragingly as 
well, 32.4% of prescribers routinely referred to the NSTG on 
a daily basis when making prescribing decisions with 18.9% 
referring the NSTG once a week, higher than the previous 
study by Akpabio et al. [12]. In addition, a high number of 
prescribers (82%) found it easy to refer to the NSTGs when 
needed although concerns with the lack of training (Table 2) 
similar to South Africa [31].
The prescribers reported using a wide variety of reference 
sources when prescribing medicines (Table 1, Fig. 2). Most 
Table 5  Strategies to increase the use of STGs
Strategy (theme) Suggestions for the future
Access to essential medicines The medicines included in the essential medicine list (Nemlist) should be available all the times. The 
medications listed for treatment in the STG should be on the Nemlist and available in stock always
Training on use of STG/refresher courses The MoHSS should provide continuous refresher courses for prescribers; this will promote prescrib-
ers to make correct references of symptoms and treatments “There is a need to include a list of 
available medicine in each health facility level as well as their common side effects”
Updating guidelines Prescribers recommended posting of guidelines for identified recurrent problems (wrong prescrip-
tions). Make them more available; update them to match current global medical guidelines. “The 
STGs should be up-to-date and based on current literature”. “It needs to be updated to accommo-
date the hospital level fully (and not referred to the hospital)”
Access and availability of STG Every staff member must have his/her own book. STGs should be available commercially at reason-
able price. STGs should be available more frequently. “STG should be available at all health facili-
ties, wards and out-patient units”
Organization of the STG Make the smaller and more specific. “Make the STGs more focussed on nursing diagnosis and not 
general diagnosis”. “STGs must be revised and written according to the health workers’ category 
e.g. Management for nurses and doctors”. “Too much information for one condition it required a 
lot of time”. Direction on interpreting the main signs and symptoms: “Please note first the sign and 
symptoms of different diseases than the diagnosis and the treatment. “Clearly outline 1st option 
for prescribing and Second option for prescribing in case if the patient comes back with the same 
problem”. Reduce the size of the STG and make it pocket fit: “STGs should be short and concise”
STG audits Conduct regular evaluation on the use of the STG to make sure health workers adhere to it
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prescribers used printed guidelines in the form of STGs, 
as well as treatment and algorithms charts (Fig. 2), similar 
to Uganda [33]. Encouragingly, there was no mention of 
pharmaceutical companies as a source of information dif-
ferent to some LMICS [34–38], with the potential for biased 
information affecting subsequent prescribing and patient 
care [38–41].
The high use of the STGs appeared to be due to a number 
of factors including their comprehensiveness, simple and 
well-structured STGs, availability, relevance, objectivity 
and portability (Table 3). Training on STGs has reduced 
the prescribing of antibiotics and over use of injections in 
other countries [42, 43]. Objectivity and trust in prescribing 
guidance resulted in high adherence rates to the ‘Wise List’ 
in Stockholm County Council in Sweden [44–46].
Recommendations on drivers for compliance to NSTGs 
(Table 4) included increasing access to STGs and essential 
medicines at health facilities, continuous professional train-
ing, regularly updating, and continuously auditing and moni-
toring prescribing against NSTGs. These findings are also 
in line with a similar previous study conducted in a number 
of regions of Namibia [12].
Limitations
We are aware of a number of limitations with this study. The 
principal limitation is that the study was carried out in only 
one region of Namibia and with a limited number of health 
facilities. However, we believe our findings are robust based 
on the nature of the chosen sites and their representational 
characteristics. As a result, providing future guidance on ways 
to improve medicine use throughout Namibia and wider.
Conclusion
Whilst the overall awareness of STGs is high among pre-
scribers in Namibia, their use can be limited. The main fac-
tors driving the use of the STGs in Namibia are their access, 
the availability of medicines recommended by the STG, the 
simplicity and objectivity.
The findings suggest that STGs should be regularly 
revised, routinely made available to all health professionals, 
and the treatment options described in STGs should be avail-
able and in stock at all times. Pharmacists can also play a key 
role here. These are considerations for the future along with 
the introduction of a prescribing performance management 
system including agreed quality indicators. Pharmacists 
can play a key role in their development. The introduction 
of electronic prescribing systems can help with real time 
auditing of prescribing as seen with the Wise List in Sweden 
[46, 47].
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